Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Published:2019-02-28 Issue:1 Volume:18 Page:
ISSN:1475-2840
Container-title:Cardiovascular Diabetology
language:en
Short-container-title:Cardiovasc Diabetol

Author:

Cefalo Chiara Maria Assunta,Cinti Francesca,Moffa Simona,Impronta Flavia,Sorice Gian Pio,Mezza Teresa,Pontecorvi Alfredo,Giaccari Andrea

Funder

European Foundation for the Study of Diabetes

Italian Ministry of education, research and university

Università Cattolica del Sacro Cuore

FONDAZIONE ASSOCIAZIONE MEDICI DIABETOLOGI

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1186/s12933-019-0828-y.pdf

Reference103 articles.

1. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation. 2018;137(4):323–34.

2. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

3. Petersen C. Analyse des phloridzins. Ann Acad Sci Fr 1835;15:178.

4. DeFronzo RA, Goldberg M, Agus ZS. The effects of glucose and insulin on renal electrolyte transport. J Clin Investig. 1976;58(1):83–90.

5. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31–8.

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering the antidiabetic potential of heart-friendly and diuretic bioactive compounds through computer-based drug design;Computational Biology and Chemistry;2024-10

2. Gut microbiome: A revolution in type II diabetes mellitus;World Journal of Diabetes;2024-09-15

3. Sotagliflozin attenuates cardiac dysfunction and depression-like behaviors in mice with myocardial infarction through the gut-heart-brain axis;Neurobiology of Disease;2024-09

4. A Review of Sotagliflozin: The First Dual SGLT-1/2 Inhibitor;Cardiology in Review;2024-07-29

5. Progress on the mechanism of Sodium-glucose cotransporter;SCIENTIA SINICA Vitae;2024-07-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3